Inactive Instrument

Other languages Jupiter Neurosciences, Inc.

Equities

Jupiter Neurosciences, Inc. Announces Research Breakthrough with JOTROL in Parkinson's Disease	23-02-27
Jupiter Neurosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-12-02
Jupiter Neurosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-16
Jupiter Neurosciences, Inc. Announces Journal of Alzheimer's Disease Publication Highlighting Use of JOTROL™	22-06-14
Jupiter Neurosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-18
Jupiter Neurosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22-04-26
Jupiter Neurosciences, Inc. Auditor Raises 'Going Concern' Doubt	22-04-25
Jupiter Neurosciences, Inc. Announces Broadening of IP Estate for its Unique Resveratrol Formulation, JOTROL	22-03-01
Jupiter Neurosciences, Inc. Announces Completion of Phase I Safety Trial with Enhanced Resveratrol Product, JOTROL™	22-02-23

No results for this search